Abstract
Eighteen patients with advanced renal cell carcinoma (RCC) were treated by systemic administration of interleukin-2 (IL-2) from March 1986 to October 1988. All of the patients received 1 x 106 units of IL-2 twice a day for at least 4 weeks. Three patients achieved complete response (CR), 10 no change (NC) and 5 progressive disease (PD). Therefore, the response rate was 16.7%. Survival rate was compared with historical control group of 27 patients with advanced RCC in our institution. One, three and five year survival rate of the patients treated with IL-2 was 78%, 44% and 33%, although the historical group was 57%, 19% and 19%. We conclude that IL-2 can improve prognosis of patients with advanced RCC.
| Original language | English |
|---|---|
| Pages (from-to) | 348-349 |
| Number of pages | 2 |
| Journal | Biotherapy |
| Volume | 9 |
| Issue number | 3 |
| Publication status | Published - 1995 Jan 1 |
Keywords
- IL-2
- renal cell carcinoma
ASJC Scopus subject areas
- Oncology
- Cancer Research
